Posts

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

on
Yarrow Bioscience has completed a reverse merger with VYNE Therapeutics and its shares began trading on the Nasdaq under the ticker YARW on July 28, 2026, as it advances YB-101, an anti-TSHR antibody targeting Graves’ disease and thyroid eye disease. The FDA has approved Otsuka Pharmaceutical's once-daily extended-release capsule SIMTRIYO (centanafadine), a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at least 20 kg; the drug is expected to launch later in 2026 after DEA scheduling. Sources: Otsuka Receives FDA Approval for First-in-Class ... FDA Approves Otsuka's SIMTRIYO: First New ADHD ... Yarrow completes reverse merger with VYNE, enters ... Otsuka's ADHD approval opens up new drug class with ... FDA approves Simtriyo (centanafadine), a 'first of its kind' ... Yarrow blooms with $1.37B autoimmune thyroid disease deal ...

MapLight's schizophrenia drug dampens once‑daily hopes despite Phase 2 win

on

Legend Biotech CEO Ying Huang Resigns

on

AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Leerink Partners Report Names Carterra a Core Enabler of the $7B 'Lab-in-the-Loop' Antibody Discovery Market

on

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

on

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on

MapLight shares sink on mixed Phase 2 schizophrenia readout

on

FDA Approves Otsuka's Tool SIMTRIYO

on

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Sarepta Taps Former AbbVie and Tessera CEO Michael Severino as New CEO to Lead Duchenne Drugmaker's Turnaround

on

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on